APP inhibitors(Beta amyloid A4 protein inhibitors), DYRK1A inhibitors(Dual-specificity tyrosine-phosphorylation regulated kinase 1A inhibitors), α-synuclein inhibitors(Synuclein alpha inhibitors)

Therapeutic Areas

Immune System DiseasesNervous System DiseasesCongenital Disorders+ [6]

Active Indication

Alzheimer DiseaseMultiple SclerosisMuscular Dystrophy, Duchenne+ [6]

Inactive Indication

Immunoglobulin Light-Chain AmyloidosisMultiple Sclerosis, Relapsing-RemittingSenile cardiac amyloidosis

Originator Organization

Charité - Universitätsmedizin Berlin

Active Organization

University of Rochester

Charité - Universitätsmedizin Berlin

Shandong Cancer Hospital

+ [2]

Inactive Organization-

Drug Highest PhasePhase 3

First Approval Date-

RegulationOrphan Drug (US)

Structure

Molecular FormulaC22H18O11

InChIKeyWMBWREPUVVBILR-WIYYLYMNSA-N

CAS Registry989-51-5

Clinical Trials associated with (-)-Epigallocatechin Gallate

NCT06068543 / Not yet recruitingPhase 2IIT

A Phase 2 Randomized Controlled Trial of Epigallocatechin-3-Gallate (EGCG) on Frailty and Inflammation in Older Survivors of Cancer

This study is a two-arm placebo controlled randomized clinical trial, to assess the effect of a 12-week EGCG intervention on physical frailty compared to placebo in pre-frail older cancer survivors.

Start Date01 Jul 2024

Sponsor / Collaborator

University of Rochester

NCT06398405 / RecruitingPhase 2IIT

Efficacy and Safety of Epigallocatechin-3-gallate, an Important Polyphenolic That Originates From Tea, in Patients With Esophageal Squamous Cancer: A Phase II Trial

The investigators conduct this phase II study to evaluate safety and effectiveness of EGCG in patients with dysphagia. Swallowing-related dysphagia and pain scores were recorded using the numerical rating scale (NRS) daily . Barium meal radiography was utilized to measure the luminal size and the length of the lesion area both before and after a week of EGCG treatment. The scales are translated into Chinese and guides in Chinese are developed instructing how to use the scales and perform the assessments.

Start Date22 Apr 2024

Sponsor / Collaborator

Shandong Cancer Hospital

NCT06265532 / RecruitingPhase 1IIT

Collagen-targeted PET Imaging for Assessment of EGCG Effect

The primary purpose of this substudy is to determine if collagen-targeted PET using the type 1 collagen-targeted PET probe, Gallium-68 (68Ga)-labeled collagen binding probe 8 (CBP8) can inform as to drug effect of EGCG and assist in dose selection.

Start Date07 Feb 2024

Sponsor / Collaborator

The University of California, San Francisco

[+3]

100 Clinical Results associated with (-)-Epigallocatechin Gallate

100 Translational Medicine associated with (-)-Epigallocatechin Gallate

100 Patents (Medical) associated with (-)-Epigallocatechin Gallate

9,009

Literatures (Medical) associated with (-)-Epigallocatechin Gallate

31 Dec 2024·Journal of enzyme inhibition and medicinal chemistry

Identification of potential inhibitors against Staphylococcus aureus shikimate dehydrogenase through virtual screening and susceptibility test

Article

Author: Zhu, Mengfan ; Qu, Jinfeng ; Deng, Qi

Staphylococcus aureus shikimate dehydrogenase (SaSDH) plays a crucial role in the growth of Staphylococcus aureus (S. aureus), but absent in mammals and therefore a potential target for antibacterial drugs to treat drug-resistant S. aureus infection. In this study, a 3D model of SaSDH was constructed by homology modelling and inhibitors of SaSDH were screened through virtual screening. (-)-Gallocatechin gallate and rhodiosin were identified as inhibitors with K_is of 2.47 μM and 73.38 μM, respectively. Molecular docking and isothermal titration calorimetry showed that both inhibitors interact with SaSDH with a K_D of 44.65 μM for (-)-gallocatechin gallate and 16.45 μM for rhodiosin. Both inhibitors had antibacterial activity, showing MICs of 50 μg/mL for (-)-gallocatechin gallate and 250 μg/mL for rhodiosin against S. aureus. The current findings have the potential for identification of drugs to treat S. aureus infections by targeting SaSDH.

01 Dec 2024·Molecular biology reports

Oxidative stress in Alzheimer’s disease: current knowledge of signaling pathways and therapeutics

Review

Author: Sharma, Prajjwal ; Singh, Sunil K ; Dhapola, Rishika ; HariKrishnaReddy, Dibbanti ; Beura, Samir K

Alzheimer's disease's pathophysiology is still a conundrum. Growing number of evidences have elucidated the involvement of oxidative stress in the pathology of AD rendering it a major target for therapeutic development. Reactive oxygen species (ROS) generated by altered mitochondrial function, dysregulated electron transport chain and other sources elevate aggregated Aβ and neurofibrillary tangles which further stimulating the production of ROS. Oxidative stress induced damage to lipids, proteins and DNA result in neuronal death which leads to AD. In addition, oxidative stress induces apoptosis that is triggered by the modulation of ERK1/2 and Nrf2 pathway followed by increased GSK-3β expression and decreased PP2A activity. Oxidative stress exaggerates disease condition by interfering with various signaling pathways like RCAN1, CREB/ERK, Nrf2, PP2A, NFκB and PI3K/Akt. Studies have reported the role of TNF-α in oxidative stress stimulation that has been regulated by drugs like etanercept increasing the level of anti-oxidants. Other drugs like pramipexole, memantine, carvedilol, and melatonin have been reported to activate CREB/RCAN1 and Nrf2 pathways. In line with this, epigallocatechin gallate and genistein also target Nrf2 and CREB pathway leading to activation of downstream pathways like ARE and Keap1 which ameliorate oxidative stress condition. Donepezil and resveratrol reduce oxidative stress and activate AMPK pathway along with PP2A activation thus promoting tau dephosphorylation and neuronal survival. This study describes in detail the role of oxidative stress in AD, major signaling pathways involving oxidative stress induced AD and drugs under development targeting these pathways which may aid in therapeutic advances for AD.

01 Dec 2024·Molecular biology reports

Regulation of gene expression by modulating microRNAs through Epigallocatechin-3-gallate in cancer

Review

Author: Dharshini, Loganathan Chandramani Priya ; Mandal, Abul Kalam Azad

Cancer is an intricate ailment that has a higher death rate globally and is characterized by aberrant cell proliferation and metastasis in nature. Since the beginning of healthcare, natural products, especially those derived from plants, have been utilized to support human health. Green tea contains an essential catechin called epigallocatechin gallate, which has anti-proliferative, anti-mutagenic, anti-inflammatory, and antioxidative properties. The anticancer properties of EGCG have been extensively studied using pre-clinical cell culture and animal model systems. Dysregulated miRNA may be a biomarker since it influences the different characteristics of cancer like upholding proliferative signaling, cell death, invasiveness, metastasis, and angiogenesis. EGCG either elevates or lowers the expression of dysregulated miRNAs in cancer. Nonetheless, due to its anticancer properties, greater attention has been paid towards the development of efficient strategies for utilizing EGCG in cancer chemotherapy. This review summarizes the modifying effect of EGCG on miRNAs in cancer after briefly discussing the anticancer mechanisms of EGCG and the function of miRNAs in cancer.

News (Medical) associated with (-)-Epigallocatechin Gallate

07 Apr 2024

·www.prnewswire.com

Nucific Invites You To Nuture Your Gut Microbiome and Celebrate World Health Day with Nucific Bio-X4

Enjoy a Slimmer Waistline, More Energy, Smoother Digestion, and Boosted Confidence with 4-in-1 Probiotic Support LOS ANGELES, April 7, 2024 /PRNewswire/ -- World Health Day, observed annually on April 7th, serves as a global platform to raise awareness about pressing health issues and advocate for universal healthcare access. It aims to mobilize individuals and communities to take proactive steps towards maintaining and improving their health. Continue Reading Nucific Bio-X4 is a groundbreaking weight support formula made from science-backed ingredients chosen to help boost metabolism, fight unhealthy cravings, and help you achieve your weight loss goals.†* Renowned nutritionist and Nucific® founder, Dr. Amy Lee stresses the significance of nurturing your microbiome as the cornerstone of overall health. Gut health is pivotal in digestion, nutrient absorption, and immune function. Additionally, the gut microbiome impacts various health aspects, such as mental well-being, weight management, and healthy skin. In reality, supporting your good gut bacteria is key for supporting every aspect of health. Nucific's Dr. Amy Lee recommends taking care of your gut health in honor of World Health Day with supplements like Nucific BIO-X4. Nucific Bio-X4 is a groundbreaking weight support formula that contains advanced probiotics, which flood your gut with healthy slimming power. These probiotics work synergistically to help boost metabolism, combat unhealthy cravings, and assist you in achieving your weight loss goals.† By prioritizing gut health with probiotic-rich supplements like Nucific Bio-X4, individuals can take proactive steps towards achieving a healthy weight, renewed youthful vitality and youthful-looking skin.†* What is Nucific BIO-X4? Nucific BIO-X4 offers a comprehensive approach to weight management and gut health with its 4-in-1 probiotic formula. Your gut health consists of 4 key factors: Your microbiome, digestive enzymes, metabolism, and appetite. Nucific BIO-X4 is uniquely formulated to support all of these systems for smoother digestion, better nutrient absorption, faster fat-burning, and fewer junk food cravings — all in one easy-to-use blend.†* To support optimal digestion and promote a slimmer body, NucificBio-X4 combines four key ingredient blends: green tea extract (EGCG), Caralluma Fimbriata, potent probiotics, and digestive enzymes. By supporting gut health with Nucific Bio-X4, individuals can experience not only a leaner physique but also more energy, sharper focus, a younger appearance, and renewed vitality.†* Nucific Bio-X4 Key Ingredients Probiotics: A potent blend of five powerful bacterial strains, including Lactobacillus and Bifidobacterium, to support smooth digestion and easier weight management. These strains work together to soothe the gut and contribute to overall digestive comfort, helping promote a healthier digestive tract.†* EGCG: Derived from green tea, EGCG is a natural compound known for its metabolism-boosting properties. Numerous studies have shown its ability to support metabolic rate, helping users achieve a slimmer physique while providing the energy to enjoy each day to the fullest.†* Caralluma Fimbriata: This edible cactus high in fiber aids in curbing unhealthy food cravings, a significant step towards achieving desired body goals. By helping users resist tempting snacks and unhealthy foods, this compound supports dietary discipline and assists in maintaining a healthy waistline.†* Digestive Enzymes (Amylase, Lipase, Bromelain): A blend of digestive enzymes to efficiently break down foods, unlocking their nutrients and alleviating digestive issues. Amylase, lipase, and bromelain work synergistically to enhance nutrient absorption, promoting overall well-being from head to toe.†* Where to Purchase Nucific Bio-X4 Nucific BIO-X4 is available for sale on the Nucific website for the price of $99 with a 90-day purchase price refund guarantee. Discounts are also periodically available for Nucific email subscribers and text club members. About Nucific Nucific believes great nutrition is the key to a healthy mind and body. This has led the wellness brand and its creators to develop some of the most advanced supplements on the market. Backed by Dr. Amy Lee, the Nucific product line helps people from all walks of life look and feel their best. The brand's other whole-body health support formulas include Carb-C6, Deep Cell Activator, and Nighttime Slimming Complex. Nucific's products contain premium ingredients that are third-party tested for quality. For more information, visit or @nucific on Instagram. About Dr. Amy Lee Dr. Amy Lee is a member of the National Board of Physician Nutrition Specialists and board certified by the American Board of Internal Medicine. Serving as the Chief Medical Officer in more than 30 nutrition clinics, Dr. Lee creates optimized diet plans for her patients, helping them achieve their weight goals and supporting their overall well-being. She is also co-author of the recent book, Access: Addressing the Obesity Crisis. Dr. Lee is a nutritional expert in the media as well appearing in outlets like Forbes, Yahoo!, The Healthy, Healthline, and so much more. Her continued research allows her to create innovative nutritional supplements to help people across the world look and feel their absolute best. For more information visit, dramylee.com and follow @dramy_lee on Instagram. †These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. *All individuals are unique. Your results can and will vary. Press Contact: Laura Baumgartner - Asylum PR [email protected] SOURCE Nucific

11 Sep 2023

·www.sciencedaily.com

Ceramic tea set glazing affects health benefits of tea, finds new study

Tea contains flavonoids such as catechins, which have numerous health benefits. Now, researchers reveal that the glazing on ceramic tea sets plays a crucial role in retaining the beneficial components of tea. By examining the effects of different glazes on the catechin content in green tea, they find that the choice of glaze materials affects the concentration of these compounds, as well as the color and flavor of tea. Tea contains flavonoids such as catechins, which have numerous health benefits. Now, researchers from Nagoya Institute of Technology, Japan, reveal that the glazing on ceramic tea sets plays a crucial role in retaining the beneficial components of tea. By examining the effects of different glazes on the catechin content in green tea, they find that the choice of glaze materials affects the concentration of these compounds, as well as the color and flavor of tea. Introduced as a medicinal drink around 2700 B.C., tea has grown to be the one of the most popular beverages worldwide. One of the key reasons for its popularity is its rich content of flavonoids and polyphenols, which contribute to the antioxidant property, flavor, and aroma of tea, offering various potential health benefits. These compounds are extracted from tea leaves during brewing and can be influenced by several factors, such as water temperature, brewing time, and the materials used in tea preparation vessels. Recently, researchers from Nagoya Institute of Technology (NITech) in Japan have revealed, for the first time, that the choice of glazing on ceramic tea sets used to prepare tea plays a key role in the retention of catechin flavonoids. In their study published online in the journal Scientific Reports on June 28, 2023, Associate Professor Takashi Shirai, along with Dr. Yunzi Xin, Mr. Sota Shido, and Dr. Kunihiko Kato from the Advanced Ceramics Research Center at NITech, examined the impact of four different typical Japanese commercial glazes -- Oribe, Namako, Irabo, and Toumei -- on the content of catechins, the most abundant flavonoid found in green tea. While glaze coatings primarily consist of feldspar minerals, such as silicon, aluminum, sodium, and calcium oxides, they also contain distinct metal oxide species that impart a unique appearance and texture to the ceramic vessel. Oribe glaze predominantly contains copper (Cu) oxides and imparts a vibrant green color, while Namako glaze contains cobalt (Co) oxides for a dark blue appearance. Irabo glaze contains iron (Fe) oxides that impart orange tones, while Toumei glaze has a high titanium (Ti) content, providing a transparent finish. To examine the effect of the glaze on tea catechins, the researchers brewed a green tea solution using ion-exchanged water at 80°C for three minutes. The tea leaves were separated, and the supernatant (liquid lying above solid residue) was mixed with glaze powders coated on ceramic tiles. The glaze-tea mixture was then allowed to react for six hours, followed by the removal of the glaze powder through centrifugation and filtration. The researchers observed that the pristine tea solution had a clear bright yellow color, but after six hours of degradation, it turned into a yellowish-brown color. In contrast, the tea solutions degraded by different glazes exhibited darker black or brown colors. In other words, the extent of color change depended significantly on the type of glaze. Additionally, the researchers also observed a selective reduction in the amount of altered catechins in tea. The tea solutions mixed with Oribe, Namako, and Irabo glazes showed significantly lower concentrations of epicatechin, epicatechin gallate, epigallocatechin, and epigallocatechin gallate, while the Toumei glaze selectively degraded epigallocatechin gallate. The reduction in catechin concentration and the resulting color change can be attributed to the oxidation process of catechins, which forms brownish thearubigins and reddish-orange theaflavin and its oxide pigments. "During the degradation process, Cu-, Co-, Fe-, and Ti-oxides in glaze powders can act as a Lewis acid catalyst and promote the oxidation of catechin molecules to ortho-quinones, followed by further reaction to form thearubigins and/or theaflavin and its oxides. Another oxidation route is through the polymerization of intermediate free radical catechins," explains Dr. Shirai. "And it is very interesting that thearubigins and theaflavins are the main components of fermented tea like black tea. In other words, green tea brewed by specific ceramic tea sets can be turned into black tea." In summary, this study highlights that the choice of glaze materials used in ceramic tea sets can significantly affect the concentration of beneficial compounds such as catechins in tea. "The specific function of glazes on the degradation of catechins not only provides principal information for the design and development of functional materials but can also impact daily tea drinking and long-term human health-related issues," concludes Dr. Shirai.

Clinical Result

12 Jul 2023

·www.sciencedaily.com

New study using human fibroid cells supports use of green tea compound as treatment for uterine fibroids

In a pre-clinical, proof-of-concept study, researchers found that epigallocatechin gallate (EGCG), a green tea compound with powerful antioxidant properties, could be promising for both treating and preventing uterine fibroids. Results of the study add to growing evidence that EGCG may reduce fibroid cell growth. The study was specifically designed to identify the biochemical mechanisms responsible for EGCG action in fibroid cells. In a pre-clinical, proof-of-concept study from Johns Hopkins Medicine, researchers found that epigallocatechin gallate (EGCG), a green tea compound with powerful antioxidant properties, could be promising for both treating and preventing uterine fibroids. Results of the study, first posted online May 25 in Scientific Reports, add to growing evidence that EGCG may reduce fibroid cell growth. The study was specifically designed to identify the biochemical mechanisms responsible for EGCG action in fibroid cells. The investigators emphasize that their study involves human fibroid cells grown in the laboratory and treated with EGCG extract to explore the possibility of oral EGCG supplementation as a therapy, rather than just drinking cups of green tea as a preventative measure for uterine fibroids. "The purpose of this study was to examine how EGCG works to treat and prevent uterine fibroids," says James Segars Jr., M.D., professor of gynecology and obstetrics at the Johns Hopkins University School of Medicine. "There is no standard protocol for uterine fibroid disease management or prevention, no tools to prevent their growth, so finding a safe nonsurgical therapy is important." Uterine fibroids are the most common benign tumors of the uterus. Made up of smooth muscle cells and a large matrix of connective tissue, the fibroids range in size from nearly microscopic to bulky masses that can enlarge and distort the uterus. An estimated 77% of women will develop fibroids in their lifetime, most of them by age 50. Black and Hispanic women develop them at 1.5 to two times the rate of white women. While many people with uterine fibroids are without symptoms, about 25% experience significant symptoms including heavy uterine bleeding, pelvic pain and infertility. Uterine fibroids are the leading cause of hospitalizationhysterectomy in the United States, according to the U.S. Department of Health and Human Services. In addition to complete removal of the uterus, surgical treatment may include various means of removing fibroid tumors from the uterine wall. For the new study, researchers used laboratory cultures of uterine fibroids collected from living patients. Because uterine fibroid cells have a large extracellular matrix (the network of macromolecules and minerals in tissues that support, but are not part of, cells) compared to normal cells, researchers designed their experiments to see if treatment of cells with EGCG affects protein expression associated with this matrix. Specifically, they studied fibronectin, a matrix protein; cyclin D1, a protein involved with cell division; and connective tissue growth factor (CTGF) protein. Cells were dosed with 100 micromoles (a micromole is 1 millionth of a mole) per liter of EGCG in growth media for 24 hours, and then a Western blot -- a laboratory technique used to detect a specific protein in a blood or tissue sample -- was performed. In this study, researchers looked for levels of cyclin D1 and CTGF proteins in EGCG-treated fibroid cells compared to untreated cell. They found that EGCG reduced protein levels of fibronectin by 46% to 52%, compared with an untreated control group of fibroid cells. They also found that EGCG disrupted pathways involved in fibroid tumor cell growth, movement, signaling and metabolism, and they saw up to an 86% decrease in CTGF proteins compared with the control group. "The results from this study show that EGCG targets many signaling pathways involved in fibroid growth, particularly the extracellular matrix," says study lead author Md Soriful Islam, Ph.D., M.Sc., a postdoctoral fellow at the Johns Hopkins University School of Medicine. "EGCG supplements could be an easily accessible and natural way to relieve symptoms and slow fibroid growth." These results lend support to the FRIEND (Fibroids and Unexplained Infertility Treatment With Epigallocatechin Gallate; A Natural Compound in Green Tea) study (ClinicalTrials.gov identifier NCT05364008), an ongoing clinical trial of EGCG in women with fibroids who are seeking pregnancy. While results from this study show promise, researchers caution that more studies need to be done, and consumers should not try to self-dose with green tea supplements. Future research on EGCG will include clinical trials with large and diverse patient groups to determine optimal doses as well as possible side effects of EGCG supplementation. Other scientists at the Johns Hopkins University School of Medicine who contributed to this research are Maclaine Parish, Joshua Brennan and Briana Winer. Segars has been a primary investigator on research sponsored by Bayer, Abbvie, BioSpecifics Technologies Corp., Allergan and Myovant Sciences. All other authors have no conflicts to disclose. This research was partly supported by the National Institutes of Health's Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the Howard W. and Georgeanna Seegar Jones Endowment.

Clinical Result

100 Deals associated with (-)-Epigallocatechin Gallate

External Link

KEGG	Wiki	ATC	Drug Bank
-	(-)-Epigallocatechin Gallate	-	DB12116

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Muscular Dystrophy, Duchenne	Phase 3	DE	Charité - Universitätsmedizin Berlin	30 Dec 2010
Alzheimer Disease	Phase 3	DE	Charité - Universitätsmedizin Berlin	01 Oct 2009
Multiple Sclerosis	Phase 3	-	Charité - Universitätsmedizin Berlin	-
Hepatocellular Carcinoma	Phase 2	-	The University of Texas Southwestern Medical Center	01 Aug 2024
Liver Cirrhosis	Phase 2	-	The University of Texas Southwestern Medical Center	01 Aug 2024
Inflammation	Phase 2	US	University of Rochester	01 Jul 2024
Neoplasms	Phase 2	US	University of Rochester	01 Jul 2024
Deglutition Disorders	Phase 2	CN	Shandong Cancer Hospital	22 Apr 2024
Esophageal Squamous Cell Carcinoma	Phase 2	CN	Shandong Cancer Hospital	22 Apr 2024
Immunoglobulin Light-Chain Amyloidosis	Phase 2	DE	-	01 Apr 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05758571 (Phase I/II clinical trial of efficacy and safety of EGCG oxygen nebulization inhalation in the treatment of COVID-19 pneumonia patients with cancer, Pubmed)	Phase 1/2	COVID-19	60	EGCG nebulization 1760-8817umol/L	jfgsibnvhx(laldgdiati) = gwavlcxkwn anfmogcclm (krmioeocnj )	Positive	17 Apr 2024
NCT02008721 (CTgov)	Phase 3	Multiple System Atrophy	92	EGCG as putative neuroprotective agent (EGCG as Putative Neuroprotective Agent)	dwozjyefnm(jiqcjwsqgn) = ntomcfvhco zsmqfgevlz (qhyyeoekxb, nezunaibgz - yvfopbakur) View more	-	12 Mar 2024
NCT02008721 (CTgov)	Phase 3	Multiple System Atrophy	92	Placebo (Placebo)	dwozjyefnm(jiqcjwsqgn) = zdfkhcszde zsmqfgevlz (qhyyeoekxb, ttiobnvhbq - oyvbvchtwb) View more	-	12 Mar 2024
NCT02580279 (Pubmed)	Phase 1	Neoplasms \| Dermatitis	19	EGCG solution	dpcxlbfiti(nxocroajbx) = significant relief can be observed in burning sensation after 15 days of EGCG treatment vvozgenwmr (rdgulvitid ) View more	-	24 Aug 2023
NCT03928847 (CTgov)	Early Phase 1	Idiopathic Pulmonary Fibrosis	35	Epigallocatechin-3-gallate (EGCG) (EGCG PK in Healthy Volunteers 450 mg)	fwjmaywtra(lejgrtiypd) = baonlmuxvv jighbmaqti (mhjizctlbn, ximavkvzcd - miiotjiuto) View more	-	22 Dec 2022
NCT03928847 (CTgov)	Early Phase 1	Idiopathic Pulmonary Fibrosis	35	Epigallocatechin-3-gallate (EGCG) (EGCG PK in Healthy Volunteers 750 mg)	fwjmaywtra(lejgrtiypd) = hkrlgvvuiu jighbmaqti (mhjizctlbn, xvabyzkneo - ihfosuiwbc) View more	-	22 Dec 2022
ChiCTR2000029831 (Pubmed \| BMC Oral Health)	Early Phase 1	Chronic Periodontitis	20	SRP plus EGCG medication	nztjfszxmo(jbvghusvpt) = uxcjltkpdi jnmoiilnwe (bxufeowwmo ) View more	-	18 Feb 2021
NCT01928485 (CTgov)	Phase 2	Prostatic Cancer	6	active surveillance (Arm A (Active Surveillance))	xwzrjejrmp(okpzeidusi) = ewrcndpvgd xmoricnnqo (yoctjdmtbl, xlaivlbjms - xyqnmxpqyz) View more	-	03 Mar 2020
NCT01928485 (CTgov)	Phase 2	Prostatic Cancer	6	laboratory biomarker analysis+Sunphenon (Arm B (Sunphenon))	xwzrjejrmp(okpzeidusi) = tgqqwjurmd xmoricnnqo (yoctjdmtbl, oeibdrgnqr - uajfbsclzo) View more	-	03 Mar 2020
PROMESA (MDS2018)	Phase 2/3	Multiple System Atrophy	127	EGCG	tjqqosmwim(bhvvfazbes) = Individual cases of hepatotoxicity in the EGCG group show that the limit of maximal tolerable doses was reached ycepxuqncd (mosoqkxhbb ) View more	Negative	05 Oct 2018
MP259 (ERA2017)	Not Applicable	Nephrotoxicity proteinuria \| nitric oxide \| malondialdehyde	20	EPIGALLOCATECHIN GALLATE	avnrynijib(zvuuhudpgf) = yyeewipxrk tvaqunvgul (spocwsxcxo, 5.4)	Positive	26 May 2017
MP259 (ERA2017)	Not Applicable	Nephrotoxicity proteinuria \| nitric oxide \| malondialdehyde	20	EPIGALLOCATECHIN GALLATE	avnrynijib(zvuuhudpgf) = hxtipeymho tvaqunvgul (spocwsxcxo, 9.9)	Positive	26 May 2017
AAAAI2017	Phase 1	HIV Infections IgE	22	PolyphenonE 800mg	qplxyospnm(djfpfmfugk) = wuuxngayyl vysoehmdor (vocgnzdrsm, 229) View more	Positive	01 Feb 2017
NCT02147041 (Pubmed \| Clin Nutr)	Phase 2/3	Weight Loss	115	High-dose green tea extract	snibdnfkzz(tfnhaymlvk) = ykgboaahbt dnbqjntswm (cruvkfhyjv ) View more	Positive	01 Jun 2016

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis